Kyowa Kirin to regain control of rocatinlimab development, commercialization

Kyowa Kirin (KYKOF) announced the termination of the current rocatinlimab development and commercialization collaboration with Amgen. Kyowa Kirin will regain control of the global rocatinlimab program, including regulatory filings and future commercialization. This business decision is the result of a strategic portfolio prioritization by Amgen (AMGN). The companies are initiating a smooth and orderly transition of the program, with a focus on ensuring continuity for participants currently enrolled in clinical trial programs. Amgen will continue to manufacture rocatinlimab.